Analyses of lymphocyte tumor recruitment across treatment groups recapitulate our earlier observation, with combination therapy yielding a significant increase in total infiltrating CD8 T lymphocytes (Fig. 5d), identified using the gene expression markers Cd3d, Cd8a, Cd8b1 as previously described36. This evidence concerns the gene CD8B and neoplasm.